Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 4;2(1):oeac005.
doi: 10.1093/ehjopen/oeac005. eCollection 2022 Jan.

Incidence and natural history of coronary evagination after implanted biodegradable polymer sirolimus-eluting stent

Keiko Tsuji  1 , Masaru Ishida  1 , Tomonori Itoh  1 , Takumi Kimura  1 , Tatsuo Kikuchi  2 , Munenori Okubo  3 , Takatoshi Hayashi  4 , Hiromasa Otake  5 , Toshiro Shinke  5   6 , Yoshihiro Morino  1
Affiliations

Incidence and natural history of coronary evagination after implanted biodegradable polymer sirolimus-eluting stent

Keiko Tsuji et al. Eur Heart J Open. .

Erratum in

Abstract

Aims: The incidence and temporal change in coronary evagination (CE) after first-generation drug-eluting stent implantation is well established, whereas that after biodegradable polymer sirolimus-eluting stent (BP-SES) implantation has not yet been evaluated. The aim of this study is to assess the incidence and natural history of CE after BP-SES implantation.

Methods and results: In this multicenter registry, stable coronary lesions treated by Ultimaster BP-SES were evaluated by serial optical frequency domain imaging (OFDI) (at 0-1-12 or 0-3-12 months) and the incidence of CE was assessed. Coronary evagination was defined as the presence of an outward bulge in luminal vessel contour between apposed struts according to the following criteria: (i) evagination depth ≥10% of nominal stent diameter and (ii) evagination length ≥3.0 mm. Optical frequency domain imaging was obtained in 98, 47, 49, and 87 lesions at 0, 1, 3, and 12 months, respectively. Coronary evagination was observed in 20 (42.6%) and 12 (24.5%) lesions at 1 and 3 months, respectively, and all but one CE had resolved at 12 months. At 12 months, the mean CE area was almost zero and the mean malapposed stent area was also decreased. Comparison of the serial OFDI images indicated that CEs originated mostly from acute stent malapposition or coronary dissection behind the implanted stent.

Conclusions: In stable lesions, CE was occasionally observed with Ultimaster BP-SES at 1-3 months but mostly resolved within 12 months, without late-acquired stent malapposition. These findings suggest the safety and feasibility of biodegradable polymer coating on DES.

Keywords: Biodegradable polymer; Chronic coronary syndrome; Drug-eluting stent; Optical frequency domain imaging; Percutaneous coronary intervention.

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
Figure 1
Figure 1
Study flow chart. OFDI, optical frequency domain imaging; PCI, percutaneous coronary intervention.
Figure 2
Figure 2
Serial change of mean malapposed area (A) and representative optical frequency domain imaging images showing relative factors and natural history of coronary evagination (B). Retrospective assessment of the post-percutaneous coronary intervention optical frequency domain imaging images could be classified as four types; acute stent malapposition (Type A, white arrow), coronary dissection behind implanted stent (Type B, white arrow), smooth tissue prolapse into the lumen between struts (Type C, white arrow), thrombus or irregular protrusion (Type D, white arrow). ANOVA, repeated-measures analysis of variance; PCI, percutaneous coronary intervention. †Coronary evagination (at 1–3 months follow-up), white arrowhead; resolution of coronary evagination (at 1-year follow-up).
See this image and copyright information in PMC

References

    1. Souteyrand G, Amabile N, Mangin L, Chabin X, Meneveau N, Cayla G, Vanzetto G, Barnay P, Trouillet C, Rioufol G, Range G, Teiger E, Delaunay R, Dubreuil O, Lhermusier T, Mulliez A, Levesque S, Belle L, Caussin C, Motreff P; PESTO Investigators. Mechanisms of stent thrombosis analysed by optical coherence tomography: insights from the national PESTO French registry. Eur Heart J 2016;37:1208–1216. - PubMed
    1. Saito S, Valdes-Chavarri M, Richardt G, Moreno R, Iniguez Romo A, Barbato E, Carrie D, Ando K, Merkely B, Kornowski R, Eltchaninoff H, James S, Wijns W; on behalf of CENTURY II Investigators. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. Eur Heart J 2014;35:2021–2031. - PMC - PubMed
    1. Itoh T, Otake H, Kimura T, Tsukiyama Y, Kikuchi T, Okubo M, Hayashi T, Okamura T, Kuramitsu S, Morita T, Sonoda S, Ishihara S, Kuriyama N, Isshiki T, Soeda T, Hibi K, Shinke T, Morino Y; MECHANISM-ULTIMASTER Study Group. A serial optical frequency-domain imaging study of early and late vascular responses to bioresorbable-polymer sirolimus-eluting stents for the treatment of acute myocardial infarction and stable coronary artery disease patients: results of the MECHANISM-ULTIMASTER study. Cardiovasc Interv Ther 2021; doi: 10.1007/s12928-021-00777-4. - PMC - PubMed
    1. Radu MD, Raber L, Kalesan B, Muramatsu T, Kelbaek H, Heo J, Jorgensen E, Helqvist S, Farooq V, Brugaletta S, Garcia-Garcia HM, Juni P, Saunamaki K, Windecker S, Serruys PW. Coronary evaginations are associated with positive vessel remodelling and are nearly absent following implantation of newer-generation drug-eluting stents: an optical coherence tomography and intravascular ultrasound study. Eur Heart J 2014;35:795–807. - PubMed
    1. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701–705. - PubMed